Veracyte, Inc. will present results at the American Thoracic Society (ATS) 2016 International Conference from multiple trials supporting the company’s genomic tests that may resolve uncertainty in lung disease diagnosis. The company will present eight studies, two of them as podium presentations.

Four presentations will specify clinical data to show the cost-effectiveness, medical utility, and analytic confirmation of Veracyte’s Percepta^® Bronchial Genomic Classifier. Used to improve lung cancer diagnosis, Percepta is designed to reduce the number of invasive biopsies and other procedures that typically follow inconclusive bronchoscopy results. It helps identify low risk patients (less than 10% risk), who can be considered for low-dose computed tomography (CT) monitoring.

The other four presentations will concentrate on Veracyte’s classifier currently in development that aims to differentiate idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases. Results will emphasize the diagnostic challenges related with IPF, and the potential of the company’s classifier to tackle those challenges for more informed, less invasive clinical decision making.

“Data being presented at this year’s ATS conference further expand the substantial library of evidence demonstrating the ability of our Percepta classifier to help reduce unnecessary invasive procedures in lung cancer diagnosis,” said Bonnie Anderson, president and chief executive officer of Veracyte, in a May 3 press release. “Additionally, we are excited to showcase multiple posters confirming the potential of our ILD classifier to help clinicians deliver more accurate and timely IPF diagnosis, without the need for surgery.”

The ATS 2016 International Conference will be held May 13-18, in San Francisco, Calif.

Studies to be presented at podiums at the ATS conference event:

• May 17, 2:15-4:15 p.m., Moscone Center Room 306/308: J. Scott Ferguson, MD, University of Wisconsin, Madison will present “Impact of a bronchial genomic classifier on clinical decision making in patients undergoing diagnostic evaluation for lung cancer”.
• May 17, 2:15-4:15 p.m., Moscone Center Room 306/308: David Feller-Kopman, MD, Johns Hopkins School of Medicine will present “Cost-effectiveness of the Percepta Bronchial Genomic Classifier for the diagnostic evaluation of lung cancer: An analytical framework based on the AEGIS studies”.

Poster presentations scheduled at the ATS conference:

• May 15, 9:00-11:00 a.m., Moscone Center Room 304:  Duncan Whitney, Ph.D., Veracyte, Inc., on “Analytical performance of a bronchial genomic classifier.” See poster #A1295.
• May 15, 11:00 a.m.-12:45 p.m., Moscone Center Area D, Hall D: Giulia C. Kennedy, Ph.D., Veracyte, Inc., on “Bridging the gap between HRCT and final IPF diagnosis: Classifying the usual interstitial pneumonia pattern in transbronchial biopsies using machine learning on high dimensional genomic data.” See poster #A2381.
• May 15, 9:00-11:00 a.m., Moscone Center Room 304:  Dr. Anil Vachani, MD, University of Pennsylvania School of Medicine, on “Modeling the utility of a bronchial genomic classifier on procedure utilization in patients with suspected lung cancer.” See poster #A1287.
• May 17, 2:15-4:15 p.m., Moscone Center Room 304: Dr. Xiaoping Wu, Weill Cornell Medical College, on “The clinical utility of a genomic diagnostic test in differentiating usual interstitial pneumonia from other interstitial lung disease pathologies.” See poster #A6227.
• May 17, 2:15-4:15 p.m., Moscone Center Room 304: Dr. Urooj Imtiaz, Veracyte, Inc., on“A multicenter, prospective, blinded comparison of local histopathology and expert pathology panel diagnosis in ILD.” See poster #A5098.
• May 18, 9:00-11:00 a.m., Moscone Center Room 304: Dr. Gregory P. Cosgrove, Pulmonary Fibrosis Foundation, on “Interstitial Lung Disease Patient Diagnostic Journey (INTENSITY) Survey.”  See poster #A7894.